[HTML][HTML] Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible
V Gristina, M La Mantia, M Peri, F Iacono… - Critical Reviews in …, 2023 - Elsevier
Liquid biopsy has gained increasing interest in the growing era of precision medicine as
minimally invasive technique. Recent findings demonstrated that detecting minimal or …
minimally invasive technique. Recent findings demonstrated that detecting minimal or …
The use of minimal residual disease in thoracic oncology: Gaps between promises and the on‐the‐ground reality of daily practice
P Hofman, MG Denis - Cytopathology, 2024 - Wiley Online Library
The assessment of minimal residual disease (MRD) from blood samples of patients with
resected non‐small cell lung carcinoma (NSCLC) is promising and opens up many …
resected non‐small cell lung carcinoma (NSCLC) is promising and opens up many …
Highly Sensitive Enrichment of Low-Frequency Variants by Hairpin Competition Amplification
Z Liu, R Zhang, X Jiang, L Ji, P Sun, Y Ji… - Analytical …, 2023 - ACS Publications
Gene mutations are inevitably accumulated in cells of the human body. It is of great
significance to detect mutations at the earliest possible time in physiological and …
significance to detect mutations at the earliest possible time in physiological and …
Parallel analysis of pre-and postoperative circulating tumor DNA and matched tumor tissues in resectable pancreatic ductal adenocarcinoma: a prospective cohort …
JS Lee, Y Han, WG Yun, W Kwon, H Kim… - Clinical …, 2022 - academic.oup.com
Abstract Background Circulating tumor DNA (ctDNA) is a promising biomarker for early
tumor detection and minimal residual disease (MRD) assessment in early-stage cancer, but …
tumor detection and minimal residual disease (MRD) assessment in early-stage cancer, but …
Dynamic analysis of predictive biomarkers for radiation therapy efficacy in non-small cell lung cancer patients by next-generation sequencing based on blood …
X Zhang, X Huang, Y Cao, Y Mao, Y Zhu… - … -Research and Practice, 2023 - Elsevier
Purpose Radiotherapy plays an important role in the treatment of non-small cell lung cancer,
and the aim of this study was to explore the potential association of single gene mutation or …
and the aim of this study was to explore the potential association of single gene mutation or …
Identification of DNA variants at ultra-low variant allele frequencies via Taq polymerase cleavage of wild-specific blockers
Z Liu, X Li, R Zhang, L Ji, L Gong, Y Ji, F Zhou… - Analytical and …, 2023 - Springer
Detecting mutations related to tumors holds immense clinical significance for cancer
diagnosis and treatment. However, the presence of highly redundant wild DNA poses a …
diagnosis and treatment. However, the presence of highly redundant wild DNA poses a …
[HTML][HTML] The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
A Verlicchi, M Canale, E Chiadini, P Cravero, M Urbini… - Life, 2023 - mdpi.com
Lung cancer (LC) is the deadliest malignancy worldwide. In an operable stage I–III patient
setting, the detection of minimal residual disease (MRD) after curative treatment could …
setting, the detection of minimal residual disease (MRD) after curative treatment could …
[HTML][HTML] Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer
P Akkhasutthikun, P Kaewsapsak… - Cancer Research and …, 2024 - ncbi.nlm.nih.gov
Purpose The epidermal growth factor receptor (EGFR) mutation is a widely prevalent
oncogene driver in non–small cell lung cancer (NSCLC) in East Asia. The detection of EGFR …
oncogene driver in non–small cell lung cancer (NSCLC) in East Asia. The detection of EGFR …
[HTML][HTML] 循环肿瘤DNA 作为实体肿瘤微小残留病标志物的研究进展
陈颖 - Chinese Journal of Contemporary Pediatrics, 2023 - ncbi.nlm.nih.gov
循环肿瘤DNA（ circulating tumor DNA, ctDNA） 作为评估肿瘤的新标志物，
具有高灵敏度和特异度、 创伤小且无放射性等优点， 目前有基因测序及聚合酶链式反应等多种 …
具有高灵敏度和特异度、 创伤小且无放射性等优点， 目前有基因测序及聚合酶链式反应等多种 …
Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors
Y Chen - Zhongguo Dang dai er ke za zhi= Chinese Journal of …, 2023 - europepmc.org
循环肿瘤 DNA (circulating tumor DNA, ctDNA) 作为评估肿瘤的新标志物,
具有高灵敏度和特异度, 创伤小且无放射性等优点, 目前有基因测序及聚合酶链式反应等多种 …
具有高灵敏度和特异度, 创伤小且无放射性等优点, 目前有基因测序及聚合酶链式反应等多种 …